Independent
Tenure on this board
4.7 yrs
Also a director at
Neogenomics Inc (NEO)Dmc Global Inc (BOOM)
Meeting calendar
PRME · Annual meeting · Friday, June 5, 2026
Prime Medicine Inc
2 nominees · 2 ballot items.
Two proposals: (1) Elect Michael Kelly and David Schenkein, M.D. as Class I directors for three-year terms ending in 2029; (2) Ratify PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Market cap
$627M
1Y TSR
-14.1%
Board grade
D
Record date
Apr 9, 2026
Filing
DEF 14A
Meeting concluded · Jun 5, 2026
Follow how the vote landed and what changed on Prime Medicine Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class I Directors — Michael Kelly and David Schenkein, M.D.
ManagementBoard: FORElect Michael Kelly and David Schenkein, M.D. as Class I directors, each to serve a three-year term ending at the 2029 annual meeting.
- 2
Ratification of Independent Registered Public Accounting Firm — PricewaterhouseCoopers LLP
ManagementBoard: FORRatify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
6.9 yrs
Also a director at
Denali Therapeutics Inc (DNLI)Regeneron Pharmaceuticals Inc (REGN)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Alphabet Inc. | 9.2% | 16,562,498 | $58M |
| 2 | STATE STREET CORP | 3.5% | 6,345,125 | $22M |
| 3 | ARK Investment Management LLC | 3.5% | 6,246,827 | $22M |
| 4 | T. Rowe Price Investment Management, Inc. | 3.0% | 5,481,893 | $19M |
| 5 | BlackRock, Inc. | 2.6% | 4,679,241 | $16M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 4,474,162 | $16M |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 2.3% | 4,123,365 | $14M |
| 8 | Casdin Capital, LLC | 1.8% | 3,167,175 | $11M |
| 9 | BlackRock, Inc. | 1.7% | 3,016,314 | $10M |
| 10 | Woodline Partners LP | 1.7% | 3,003,313 | $10M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Prime Medicine Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$724M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.8B
Reference
Frequently asked questions
- When is the Prime Medicine Inc 2026 annual meeting?
- Prime Medicine Inc (PRME) holds its 2026 annual shareholder meeting on Friday, June 5, 2026.
- What is the record date for the Prime Medicine Inc 2026 meeting?
- The record date for the Prime Medicine Inc 2026 meeting is Thursday, April 9, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Prime Medicine Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Prime Medicine Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Prime Medicine Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Prime Medicine Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.